TON - October 2022 Vol 15, No 5

From The Editor October 2022
In the October issue of The Oncology Nurse-APN/PA (TON), we feature a variety of articles aimed at informing and empowering nurses, navigators, and advanced practice providers who work to improve the lives of patients with cancer. Read More ›

As New Jersey’s only National Cancer Institute–designated Comprehensive Cancer Center, Rutgers Cancer Institute of New Jersey, together with RWJBarnabas Health, has a singular focus and mission—to help patients fight cancer. Read More ›

Endocrine therapy after breast-conserving surgery may be the only treatment needed in patients aged ≥55 years with low-grade luminal type A breast cancer, sparing them radiation therapy, including its side effects, financial burden, and inconvenience, according to findings from the single-arm LUMINA clinical trial reported at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

In the phase 3 DETERMINATION trial—in which patients with newly diagnosed multiple myeloma were randomly assigned to a standard triplet regimen with and without autologous stem-cell transplantation (ASCT), with all receiving lenalidomide (Revlimid) maintenance therapy until disease progression—patients with ASCT had significantly longer progression-free survival (PFS) versus those who did not, but no difference in overall survival (OS) was observed between the 2 treatment arms. Read More ›

Minimizing some of the most distressing symptoms of cancer and its treatment requires systematic screening and risk assessment, as well as a focus on the underlying cause of these symptoms, according to experts at the European Society for Medical Oncology (ESMO) Congress 2022. Read More ›

October is Breast Cancer Awareness Month, an annual international health campaign organized by major breast cancer charities to heighten awareness of the disease and to raise funds for research into its cause, prevention, diagnosis, treatment, and cure. Read More ›

Treatment with acalabrutinib (Calquence) elicited a complete or partial response in ≥50% of patients with relapsed or refractory marginal zone lymphoma (MZL), according to interim results of a study presented by L. Elizabeth Budde, MD, PhD, Associate Professor, Hematology & Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, at the 2022 American Society of Clinical Oncology Annual Meeting. Read More ›

More than 50% of adults with refractory or relapsed large B-cell lymphoma (LBCL) who were not deemed candidates for high-dose chemotherapy and hematopoietic stem-cell transplantation (HSCT) had complete responses (CRs) following treatment with the chimeric antigen receptor (CAR) T-cell therapy lisocabtagene maraleucel (Breyanzi). Read More ›

During a special symposium at the European Society for Medical Oncology Congress 2022, a panel of experts identified some of the key challenges facing young oncology nurses and discussed strategies to better support and empower these professionals academically, clinically, and professionally. Read More ›

Digital health technologies have the potential to help transform patient care, but there are barriers that need to be overcome, said Deb Schrag, MD, MPH, George J. Bosl Chair, Department of Medicine, Memorial Sloan-Kettering Cancer Center (MSKCC), and Professor, Medicine, Weill Cornell Medical College, New York City, during a keynote lecture at the European Society for Medical Oncology Congress 2022. Read More ›

Page 1 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: